The Centers for Medicare & Medicaid Services today finalized additional provisions for the Medicare Advantage and Part D prescription drug programs beginning in 2022.

The rule permits a “preferred” specialty tier for Part D, which will provide a lower cost-sharing amount than the other specialty tier by allowing Part D plans more negotiating power with manufacturers.

The rule also codifies updates to Star Ratings for Part D plans and requires Part D plans to disclose pharmacy performance measures to CMS. Beginning in 2023, plans must provide a real-time benefit tool to help enrollees find the most cost-effective prescription drugs for their needs.

Related News Articles

Headline
The AHA today urged the Centers for Medicare & Medicaid Services to use its oversight authority for Medicare Advantage, Medicaid managed care, Children’s…
Headline
The Centers for Medicare & Medicaid Services yesterday released a request for applications from Medicare Advantage and prescription drug plans to…
Headline
The Centers for Medicare & Medicaid Services yesterday announced premium and cost-sharing information for Medicare Advantage and Part D prescription drug…
Headline
The Centers for Medicare & Medicaid Services proposes to fully phase in its new risk adjustment model for Medicare Advantage plans in calendar year 2022,…
Headline
The Centers for Medicare & Medicaid Services Aug. 4 released a proposed rule that would retroactively incorporate Medicare Advantage days into the Medicare…
Headline
Beginning July 6, both traditional Medicare and Medicare Advantage plans will cover diagnostic COVID-19 laboratory tests for nursing home residents and…